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Human Cytomegalovirus Inhibits Apoptosis by Proteasome-Mediated
Degradation of Bax at Endoplasmic Reticulum-Mitochondrion
Contacts
Aiping Zhang,a Richard L. Hildreth,a,b* Anamaris M. Colberg-Poleya,b,c,d,e
Research Center for Genetic Medicine, Children’s Research Institute, Children’s National Medical Center, Washington, DC, USAa; Molecular Medicine Program,b
Departments of Integrative Systems Biology,c Biochemistry and Molecular Biology,d and Pediatrics,e George Washington University School of Medicine and Health
Sciences, Washington, DC, USA
Human cytomegalovirus (HCMV) encodes the UL37 exon 1 protein (pUL37x1), which is the potent viral mitochondrion-local-
ized inhibitor of apoptosis (vMIA), to increase survival of infected cells. HCMV vMIA traffics from the endoplasmic reticulum
(ER) to ER subdomains, which are physically linked to mitochondria known as mitochondrion-associated membranes (MAM),
and to mitochondria. The antiapoptotic function of vMIA is thought to primarily result from its ability to inhibit Bax-mediated
permeabilization of the outer mitochondrial membrane (OMM). Here, we establish that vMIA retargets Bax to theMAM as well
as to the OMM from immediate early through late times of infection. However, MAM localization of Bax results in its increased
ubiquitination and proteasome-mediated degradation. Surprisingly, HCMV infection does not increase OMM-associated degra-
dation (OMMAD) of Bax, even though the ER andmitochondria are physically connected at the MAM. It was recently found that
lipid rafts at the plasmamembrane can connect extrinsic and intrinsic apoptotic pathways and can serve as sites of apoptosome
assembly. In transfected permissive human fibroblasts, vMIAmediates, through its cholesterol affinity, association of Bax and
apoptosome components withMAM lipid rafts. While Bax association withMAM lipid rafts was detected in HCMV-infected
cells, association of apoptosome components was not. These results establish that Bax recruitment to theMAM and its MAM-
associated degradation (MAMAD) are a newly described antiapoptotic mechanism used by HCMV infection to increase cell sur-
vival for its growth.
Human cytomegalovirus (HCMV) encodes multiple antiapo-ptotic proteins in the UL36 to UL38 loci, including the viral
mitochondrion-localized inhibitor of apoptosis (vMIA) or UL37
exon 1 (pUL37x1), UL36, and UL38 proteins and in the immedi-
ate early (IE) 1-2 locus (1–4). Both vMIA and another antiapop-
totic product, beta 2.7 RNA, inhibit mitochondrion-mediated
apoptosis in HCMV-infected cells (5–11).
vMIA is the predominant UL37 isoform from IE times and
throughout HCMV infection (12–16). vMIA is synthesized at the
endoplasmic reticulum (ER) membrane, remains membrane an-
chored by its hydrophobic N-terminal leader, and traffics from the
ER to mitochondria (17, 18). Its antiapoptotic activity is currently
ascribed to its inhibition of Bax-induced permeabilization of the
outer mitochondrial membrane (OMM) (5, 7, 8, 19, 20). How-
ever, unlike various BH3 domain-containing antiapoptotic pro-
teins, regulation of Bax function by vMIA remains poorly under-
stood (21).
HCMV vMIA traffics to ER-mitochondrion contacts known as
mitochondrion-associated membranes (MAM) (16, 17, 22, 23).
The MAM provides high-calcium (Ca2) microdomains for ER to
mitochondrial Ca2 signaling needed for basal metabolism and
sites for Ca2 homeostasis (24–27). Nonetheless, mitochondrial
Ca2 overload can initiate mitochondrion-mediated apoptosis
(28–30). HCMV vMIA causes Ca2 efflux from ER stores during
infection (31), consistent with its ability to stimulate mitochon-
drial metabolism and to blunt stress responses (32–37).
The MAM is notable for its striking enrichment of lipid syn-
thetic proteins and of internal lipid rafts (38–40). Cholesterol
binding by HCMV vMIA enables its association with MAM lipid
rafts (41). Furthermore, the MAM has been associated with pro-
tein degradation (42, 43). Erlin-1 and -2 (SPFH1 and -2), which
localize in ER lipid rafts, associate with inositol 1,4,5-trisphos-
phate receptors (IP3Rs) prior to their ubiquitination, p97 associ-
ation, and degradation by the ER-associated degradation (ERAD)
pathway. gp78 (also known as AMFR), an E3 ubiquitin ligase,
partially localizes in the MAM, initiates ubiquitination of targeted
substrates in the peripheral ER, and transfers the ubiquitinated
substrates to the central ER for their degradation by the ERAD
pathway (44–48).
It was recently found that lipid rafts at the plasma membrane
can connect extrinsic and intrinsic apoptotic pathways and can
serve as sites of apoptosome assembly, including Apaf1, Bid, cy-
tochrome c (Cyt c), procaspase 9, and caspase 3 (49, 50). Apoptosis
induction is regulated by ubiquitination and proteasomal degra-
dation of activated Bax at the OMM, known as OMM-associated
degradation (OMMAD) (51–54).
The ubiquitin-proteasome system facilitates various stages of
HCMV infection (55–58). HCMV evades the immune response
by US2- and US11-mediated targeting of the major histocompat-
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ibility complex class I (MHC-I) heavy chain to the ERAD pathway
for degradation (59–61). Furthermore, HCMV infection results in
relocalization of specific 19S proteasome subunits to the periph-
ery of nuclear viral replication centers (58).
Using quantitative proteomic analyses, we recently found that
HCMV infection dramatically alters the MAM proteome at late
times, notably increasing the abundance of Ca2 homeostasis
proteins, chaperones, and metabolic enzymes (37). Given that
vMIA binds Bax (5, 7, 8, 19, 20, 62) and is partially localized in the
MAM (18, 22, 23, 37, 41), we hypothesized that HCMV vMIA
recruits Bax to the MAM and thereby partially neutralizes its ac-
tivity in the infected cell. Indeed, our studies show that Bax is
partially retargeted to the MAM and its lipid rafts throughout
infection in HCMV-infected human foreskin fibroblasts (HFFs)
in a vMIA-dependent manner. Proteasome-mediated degrada-
tion of MAM-localized but not of mitochondrion-localized Bax is
increased in HCMV-infected HFFs. These findings establish a
novel mechanism for Bax regulation by MAM-associated degra-
dation (MAMAD) and that HCMV uses this mechanistically dis-
tinct pathway to regulate Bax levels and consequently function in
the infected cell.
MATERIALS AND METHODS
Cells and viruses. HFFs were cultured in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum (FCS) (HyClone), 100 U/ml of
penicillin, and 100 g/ml of streptomycin (Invitrogen, Gibco) as previ-
ously described (13).
The HCMV UL37x1 mutant (UL37x1 Mut or BADsubstitutionUL37x1
[BADsubUL37x1]) and its wild-type (wt) parent control HCMV (BADwt)
were graciously provided by Tom Shenk (31, 63) for these studies. HCMV
wt and HCMVUL37x1 Mut stocks were grown in HFFs, and titers were
determined as previously described (64, 65). HFFs were uninfected or
infected with HCMV wt and HCMV UL37x1 Mut at a multiplicity of
infection (MOI) of 1 or 3 PFU/cell.
Transient transfections. For fractionations, HFFs were transfected
using Lipofectamine 2000 (Invitrogen) suspended in Optimem (Gibco)
according to the manufacturer’s protocols as previously described (17, 18,
22). Twenty-four hours after transfection, adherent cells were harvested
and either stored on ice before fractionation or stored at80°C for sub-
sequent fractionation as described previously (41).
Subcellular fractionation. HCMV-infected and uninfected HFFs
were fractionated to isolate heavy MAM, mitochondrial, microsomal, and
cytosolic fractions as described previously (22, 23, 37, 66). Briefly, cells
were pelleted, resuspended in sucrose homogenization medium (SHM)
(0.25 M sucrose, 10 mM Tris [pH 7.4], and/or 10 mM HEPES [pH 7.4],
Roche complete protease inhibitor cocktail) and lysed using a motor-
driven Potter-Elvehjem homogenizer. Homogenates were pelleted by
centrifugation at 600  g for 5 min at 4°C, resuspended in SHM, and
homogenized again. The homogenates were pooled and pelleted by cen-
trifugation as described above. The cycle was repeated 2 to 4 times until a
pellet no longer formed, and aliquots of this homogenate were re-
tained as total protein. Crude mitochondria and MAM (pellet) were
separated from microsomes and cytosol (supernatant) by centrifugation
at 10,300 g for 10 min at 4°C. Ultracentrifugation (95,000 g, 60 min,
4°C) further separated microsomes (pellet) from cytosol (supernatant).
Cytosol was concentrated using 4-ml Amicon filter units (low-binding
regenerated cellulose Ultracel-4 membrane, 3 kDa) by centrifugation
(7,500  g, 30 min, 4°C). Pelleted MAM and mitochondria were resus-
pended in 300l of ice-cold mannitol buffer A (0.25 M D-mannitol, 5 mM
Tris [pH 7.4], and/or 5 mM HEPES, 0.5 mM EGTA, 1 mM phenylmeth-
ylsulfonyl fluoride [PMSF]), subjected to homogenization, and layered
onto a 10-ml 30% Percoll suspension in mannitol buffer B (0.225 M
D-mannitol, 25 mM Tris [pH 7.4], and/or 25 mM HEPES, 1 mM EGTA, 1
mM PMSF). Ultracentrifugation (95,000  g, 65 min, 4°C) was used to
band mitochondria and MAM. Collected mitochondria and MAM bands
were diluted 5-fold in either 1 phosphate-buffered saline (PBS) plus 1
mM PMSF or SHM and subjected to centrifugation to pellet mitochon-
dria (6,150 g, 10 min, 4°C) or heavy MAM (10,300 g, 10 min, 4°C). All
of the fractions were resuspended in a minimal volume (50 to 200 l) of
SHM and assayed for protein concentration using a bicinchoninic acid
(BCA) reagent kit (Pierce) according to the manufacturer’s recom-
mended protocol.
For ER/MAM and mitochondrial fractionations, pelleted cells were
resuspended in 2 ml of MTE buffer (270 mM mannitol, 10 mM Tris-HCl,
0.1 mM EDTA [pH 7.4]) supplemented with Complete protease inhibitor
cocktail (Roche) and 1 mM phenylmethylsulfonyl fluoride (PMSF)
(Sigma), and lysed by sonication (at an output power of 3.5). Cellular debris
and intact cells were removed by centrifugation at 700 g for 10 min at 4°C.
Crude mitochondria were pelleted by centrifugation at 15,000 g for 10 min
at 4°C, and the postmitochondrial supernatant was used for purification
of ER/MAM fractions. Purified mitochondria were obtained by banding
in discontinuous sucrose gradients consisting of 1.0 M and 1.7 M sucrose
steps in 10 mM Tris-HCl (pH 7.6) at 40,000  g for 22 min at 4°C.
Postmitochondrial supernatants were layered onto discontinuous sucrose
gradients (1.3, 1.5, and 2.0 M sucrose in 10 mM Tris-HCl [pH 7]) and
banded by centrifugation at 100,000 g for 45 min at 4°C. The purified
ER/MAM and mitochondrial pellets were resuspended in 1 PBS and
stored at 20°C until use. Protein concentrations of isolated subcellular
fractions were determined using a BCA assay kit (Pierce), following the
manufacturer’s recommendations.
Lipid raft isolation. Detergent-resistant membranes (DRMs) were
isolated on flotation sucrose gradients as previously described (41).
Briefly, transiently transfected HFFs (6  107 cells) were harvested by
scrapping or by trypsinization, resuspended in MBS (25 mM 4-morpho-
lineethanesulfonic acid, 150 mM sodium chloride [pH 6.5] containing
protein inhibitor cocktail [Roche at 1 tablet/50 ml or 1 mM PMSF), lysed
by Dounce homogenization and sonication (Polytron; 3 30-s bursts),
and treated with 1% Triton X-100 on ice for 30 min. Following detergent
treatment, permeabilized cell lysates were mixed 1:1 with a 90% sucrose
solution and overlaid with discontinuous layers of 35% and 5% sucrose.
Gradients were resolved by centrifugation in a Beckman SW41 rotor at
160,030  g for 18 h or at 187,813  g for 16 h at 4°C. Twelve 1-ml
fractions were sequentially collected starting from the top to the bottom of
the tube after centrifugation. Aliquots (20 to 30 l) of each gradient frac-
tion were resolved by SDS-PAGE and Western analyses.
Western analyses. Total or fractionated proteins were resolved by
SDS-PAGE in 4 to 12% Bis-Tris NuPage gels (Invitrogen) and analyzed by
Western blotting as previously described (17, 22). Blots were probed with
rabbit anti-UL37x1 (amino acids 27 to 40) antiserum (DC35; 1:2,500) (17,
22), rabbit anti-Bax (Millipore; 1:500), goat anti-Bid (Santa Cruz; 1:100);
rabbit anti-Apaf1 (Santa Cruz; 1:100); rabbit anti-procaspase 9 (GeneTex;
1:500), rabbit anti-caspase 3 (Millipore; 1:500), mouse anti-Cyt c (Abcam;
1:200), rabbit anti-fatty acid coenzyme A ligase 4 (anti-FACL4) (Abgent;
1:200), mouse anti-mitofusin 2 (anti-Mfn2) (AbCam; 1:200), rabbit anti-
PACS-2 (GeneTex; 1:500), rabbit antiprohibitin (GeneTex; 1:500), mouse
anti-caveolin 1 (anti-Cav1) (BD Biosciences; 1:500), mouse anti-glyceral-
dehyde-3-phosphate dehydrogenase (anti-GAPDH) (Sigma; 1:5,000), or
mouse anti--tubulin (Sigma; 1:2,000) and with the corresponding
horseradish peroxidase-conjugated secondary antibody (1:2,500 or
1:5,000). Reactive proteins were detected using an ECL enhanced chemi-
luminescence detection kit (Pierce). Blots were exposed to film (Denville
Scientific), and the exposures were scanned using a Bio-Rad GS-800 cal-
ibrated densitometer and analyzed using Image J Software. Digital images
were generated by using Scan Wizard Pro version 1.21 and processed in
Adobe Photoshop version CS5, 12.0.3.
Immunoprecipitation of ubiquitinated proteins. HCMV wt-in-
fected HFFs (MOI of 3) and uninfected HFFs were untreated or treated
with 2.5 M MG132 (Calbiochem) from 48 to 72 h postinfection (hpi).
Zhang et al.
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Subcellular fractions including MAM and mitochondria were isolated at
72 hpi. MAM (200g) and mitochondrial (200g) proteins were immu-
noprecipitated using ubiquitin affinity resin as recommended by manu-
facturer (Pierce ubiquitin enrichment kit from ThermoScientific). Flota-
tion gradient fractions 4 (DRMs, 200 g) and 12 (soluble proteins, 200
g) from uninfected, staurosporine (STS)-treated HFFs and from
HCMV-infected HFFs were also immunoprecipitated using the ubiquitin
affinity resin (ThermoScientific).
Flow cytometry analysis. Flow cytometry was performed as described
previously (67). Briefly, HFFs were washed twice in 1  PBS supple-
mented with 2.5% FCS, pelleted (290 g for 5 min) after each wash, and
resuspended to a final concentration of 1 106 cells/ml in 1 annexin V
(AV) binding buffer (BD Biosciences). HFFs (3  105 to 5  105 cells)
were stained with 5 l allophycocyanin-conjugated AV (BD Biosciences)
and propidium iodide (PI; 50g/ml) (BD Biosciences) for 15 min at room
temperature. Cells were examined by flow cytometry within 1 h of staining
on a FACSCaliber (BD Biosciences) fluorescence-activated cell sorter
(FACS), and data acquisition files were analyzed using FlowJo version 7.6
(TreeStar).
RESULTS
HCMV vMIA-mediated Bax recruitment to the MAM of in-
fected HFFs. HCMV vMIA, a potent antiapoptotic protein in
HeLa cells and HFFs, recruits Bax to the OMM and blocks Bax-
mediated OMM permeabilization (1, 5, 8, 9, 19, 68). vMIA, the
predominant UL37 product, traffics through the MAM (17, 22,
23), a site which affects mitochondrion-mediated apoptosis (28,
29, 69). We therefore tested whether Bax is also recruited to the
MAM during HCMV infection. To that end, we isolated subcel-
lular fractions, including the MAM, mitochondria, and cytosol,
from uninfected and HCMV-infected HFFs throughout all tem-
poral phases of infection, from IE through late times of infection
(Fig. 1). The abundance of Bax increased in the MAM and mito-
chondrial fractions from HCMV-infected HFFs at IE (8 hpi), early
(24 hpi), early/late (48 hpi), and late (72 hpi) times of infection
compared to that in uninfected HFFs. Furthermore, the relative
Bax levels, normalized to tubulin, showed increasing levels of Bax
in the MAM as well as mitochondria (bottom right). Bax recruit-
ment to the MAM and mitochondria paralleled the presence of
vMIA in those fractions. Conversely, Bax levels in the cytosol of
HCMV-infected cells decreased from IE to late times of infection
compared to those in uninfected HFFs. The relative Bax levels in
the cytosol from HCMV-infected HFFs, normalized to GAPDH in
the corresponding fractions, progressively decreased throughout
infection (bottom left). MAM markers, including FACL4 and
PACS-2, verified the identity of the MAM fraction. Importantly,
Cyt c levels increased progressively in the MAM and mitochon-
drial fractions of HCMV-infected HFFs compared to uninfected
cells. Together, these results establish that Bax is increasingly re-
cruited to the MAM and mitochondria of permissively HCMV-
infected HFFs, paralleling the presence of vMIA in those subcel-
lular compartments.
HCMV UL37 proteins are its only proteins encoded by the
virus, which are currently known to traffic to the MAM (22, 23).
To determine if vMIA plays a role in Bax recruitment to the MAM
and to mitochondria, we examined Bax levels in the MAM and
mitochondria of HCMV UL37x1 Mut-infected HFFs compared
to uninfected HFFs and parent HCMV wt-infected HFFs (31)
(Fig. 2A). Normalized Bax levels in the MAM (3.3) and in mi-
tochondria (not detected [ND]) of HCMV UL37x1 Mut-in-
FIG 1 Bax recruitment to the MAM of HCMVwt-infected HFFs. HFFs (four roller bottles each) were uninfected (Un) or infected with HCMVwt (BADwt; MOI
of 3 PFU/cell). HCMV wt-infected HFFs were harvested at 8, 24, 48, or 72 hpi. Uninfected HFFs were harvested at 72 hpi. Cells were fractionated as described
previously (22, 37, 66). Whole-cell (30 g) and fractionated (10 g) proteins were resolved by gel electrophoresis, blotted, and probed using antibodies to Bax
(1:500; Millipore), vMIA (DC35; 1:2,500), FACL4 (1:200; Abgent), PACS-2 (1:500; GeneTex), Cyt c (1:200; Abcam), -tubulin (1:2,000; Sigma), and GAPDH
(1:5,000; Sigma). The relative levels of Bax were quantified by Image J and normalized to GAPDH (left) or to -tubulin (right). The normalized Bax levels are
shown below the corresponding Western blots. Cyto, cytosol; Mito, mitochondria.
HCMV vMIA Induces Proteasome-Mediated Bax Degradation
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fected HFFs were similar to the Bax levels in MAM (4.4) and
mitochondria (ND) of uninfected HFFs. Moreover, the Bax levels
in HCMV UL37x1 Mut-infected MAM and mitochondria were
markedly lower than those in the MAM (16.9) and mitochon-
dria (4.1) of HCMV wt-infected HFFs. The absence of vMIA in
all fractions from HCMV UL37x1 Mut-infected HFFs verified
the mutant’s identity. Mfn2 and prohibitin served as controls for
ER-mitochondrion contacts (37). The inability of the HCMV
UL37x1 Mut to recruit Bax to the MAM and mitochondria es-
tablished the requirement for vMIA in Bax recruitment to the
MAM and to mitochondria of HCMV-infected HFFs.
Apoptosis of HCMV UL37x1 Mut-infected HFFs. As the
HCMVUL37x1 Mut is defective in Bax recruitment to the MAM
and to mitochondria, we tested the induction of apoptosis in in-
fected HFFs using AV binding, PI staining, and flow cytometry
(Fig. 2B). A modest increase in AV binding (AV) cells (26.4%)
was detected in HCMV UL37x1 Mut-infected HFFs at 3 days
postinfection (dpi) compared to mock-infected HFFs (9.2%) and
HCMV wt-infected HFFs (8.6%). With increasing time of infec-
tion (5 dpi), the antiapoptotic activity of vMIA during HCMV
infection of HFFs was more clearly evidenced by the increase in
AV cells in HCMV UL37x1 Mut-infected (53.6%) compared
to HCMV wt-infected (9.1%) and mock-infected (8.8%) HFFs.
Thus, HCMV UL37x1 Mut, which does not detectably recruit
Bax to the MAM or mitochondria, is functionally defective for
antiapoptotic activity in HCMV-infected HFFs.
FIG 2 (A) vMIA recruits Bax to the MAM and mitochondria during HCMV infection. HFFs were uninfected (left) or infected with HCMV wt (BADwt; middle)
or the HCMV UL37x1 Mut (BADsubUL37x1; right) at an MOI of 1 PFU/cell. Subcellular fractions were isolated at 72 hpi as previously described (22, 37, 66).
Total protein (TP; 30 g) and fractionated proteins (10 g) from purified microsomes (Mi), cytosol (Cy), MAM (M), and mitochondria (Mt) were resolved by
SDS-PAGE and examined by Western analyses for the presence of Bax (1:500; Millipore), Mfn2 (1:200; Cell Signal), vMIA (1:2,500; DC35), and prohibitin (1:500;
GeneTEX). -Tubulin (1:2,000; Invitrogen) served as a loading control. The relative levels of Bax in each fraction were normalized to the corresponding levels
of -tubulin. ND, not detected. (B) HCMVUL37x1 Mut is defective in antiapoptotic protection of infected cells. HFFs were infected with HCMV wt (BADwt)
or HCMVUL37x1 Mut (BADsubUL37x1) at an MOI of 1 or were mock infected and analyzed by flow cytometry as previously described (67). Viable cells (lower
left quadrant, AV/PI), nonapoptotic cell death (upper left, AV/PI), and apoptotic cells (lower right, AV/PI, and upper right, AV/PI) were examined
in mock-infected HFFs (left column), HCMV wt-infected HFFs (middle column), and HCMV UL37x1 Mut-infected HFFs (right column) at 3 dpi (top row)
and 5 dpi (bottom row).
Zhang et al.
5660 jvi.asm.org Journal of Virology
 o
n






MAM-localized Bax is targeted for MAMAD. The MAM lo-
calization of ubiquitin-proteasome system components and the
regulation of activated Bax by OMMAD (37, 43, 47, 51, 52) led us
to ask whether Bax in the MAM and mitochondrial fractions is
targeted for ubiquitination and proteasomal degradation (MAM-
associated degradation [MAMAD]) (Fig. 3). Ubiquitinated pro-
teins were enriched from MAM and mitochondrial fractions from
uninfected and HCMV wt-infected HFFs at 72 hpi. To measure
proteasome-mediated degradation of proteins, uninfected and
HCMV-infected HFFs were untreated or treated with MG132, a
proteasome inhibitor, from 48 to 72 hpi.
Polyubiquitinated Bax species in the MAM were more abun-
dant (2.9-fold) in MG132-treated, HCMV-infected HFFs than
in untreated, HCMV-infected HFFs (Fig. 3A, left). These results
show that ubiquitinated Bax is degraded more rapidly in HCMV-
infected HFFs in a proteasome-dependent manner. Consistent
with this finding, polyubiquitinated species of vMIA in the MAM
from HCMV-infected cells (middle) increased (13-fold) follow-
ing MG132 treatment, suggesting that ubiquitinated vMIA species
were partly targeted for MAMAD.
Importantly, proteasomal degradation of numerous ubiquiti-
nated MAM proteins was markedly increased during HCMV in-
fection (Fig. 3A, right). Ubiquitinated MAM proteins were more
abundant (3.3) in untreated, uninfected HFFs than in un-
treated, HCMV-infected HFFs. Furthermore, MG132 treatment
increased the abundance (4-fold) of ubiquitinated proteins in
the MAM fraction of HCMV-infected HFFs compared to un-
treated, HCMV-infected HFFs, whereas MG132 treatment did
FIG 3 Proteasome inhibition increases the abundance of ubiquitinated Bax in MAM (A) but not in mitochondria (B) of HCMV-infected cells. HFFs were
uninfected or infected with HCMV wt (MOI of 3). Cells were treated with the proteasome inhibitor MG132 (2.5 M) from 48 to 72 hpi. Uninfected (4 roller
bottles) and HCMV-infected (4 roller bottles) HFFs were harvested and fractionated as described previously (22, 66). MAM proteins (200g) (A) or mitochon-
drial proteins (200 g) (B) were immunoprecipitated (IP) with ubiquitin affinity resin (Pierce ubiquitin enrichment kit; Thermo Scientific). Immunoprecipi-
tated proteins were resolved by SDS-PAGE and examined by Western blot (B) analyses for the presence of Bax (left), vMIA (middle), or total ubiquitinated
proteins (right). In panel B, a longer exposure (1 min) of the mitochondrial proteins from untreated, uninfected, and HCMV-infected cells is shown below the
original exposure (5 s), corresponding to the exposure time of mitochondrial proteins from MG132-treated cells (5 s).
HCMV vMIA Induces Proteasome-Mediated Bax Degradation
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not increase the abundance (1.1) of ubiquitinated MAM pro-
teins in the uninfected HFFs. Thus, HCMV infection of HFFs
increases the proteasomal degradation of numerous MAM sub-
strate proteins, including the recruited Bax, at late times of infec-
tion. Together, these results suggest that ubiquitinated species of
Bax and vMIA are targeted for MAMAD. Moreover, the MAMAD
of numerous MAM proteins is markedly increased at late times of
HCMV infection.
Bax is recruited to the OMM by HCMV vMIA, where it blocks
Bax-dependent OMM permeabilization (5, 8, 9, 19). Bax proapop-
totic activity in mitochondria is regulated by its parkin-dependent
ubiquitination and proteasomal degradation (52). Therefore, we also
examined the ubiquitination and proteasome-mediated degradation
of mitochondrion-localized Bax and vMIA during HCMV infection
(Fig. 3B). In contrast to the MAM fraction, HCMV infection did
not specifically alter OMMAD of ubiquitinated Bax in mitochon-
dria. MG132 treatment did not markedly alter the abundance of
ubiquitinated Bax levels in mitochondria of uninfected cells or of
HCMV-infected HFFs (Fig. 3B, left). Nonetheless, MG132 treat-
ment modestly increased the abundance of ubiquitinated vMIA
species in the mitochondrial fraction of HCMV-infected HFFs
(Fig. 3B, middle), suggesting its proteasome-mediated degrada-
tion at the OMM. Total ubiquitinated mitochondrial proteins
were similar in untreated, uninfected and untreated, HCMV-in-
fected HFFs (Fig. 3B, right) (0.97). Furthermore, MG132
treatment similarly increased the abundances of ubiquitinated
proteins in mitochondria of uninfected HFFs (27.1) and of
HCMV-infected HFFs (32.6). The latter result is consistent
with the previously detected ubiquitin-proteasome pruning of the
OMM or OMMAD in uninfected cells (53, 70, 71). Nonetheless,
HCMV does not markedly alter the OMMAD of Bax or of total
ubiquitinated mitochondrial proteins during permissive infection
of HFFs.
MAM-localizedBax is partially associatedwith internal lipid
rafts. vMIA partially associates with MAM lipid rafts by its ability
to bind cholesterol (41). Lipid rafts can serve as sites of apopto-
some assembly and connections between extrinsic and intrinsic
apoptotic pathways (49, 50). To determine if Bax is recruited by
vMIA to MAM lipid rafts, we examined DRM fractions from
HCMV wt-infected HFFs and uninfected HFFs previously char-
acterized for the presence of vMIA and control Lyn (a lipid raft
marker) (41) for the presence of Bax (Fig. 4A). Bax was not de-
tectably associated with DRMs in uninfected HFFs (Fig. 4A, left).
Conversely, Bax association with DRMs was detected in HCMV
wt-infected HFFs (right) from IE (12 hpi) until late times of
HCMV infection (72 hpi).
Bax associates with ER/MAM lipid rafts. vMIA localizes to
MAM lipid rafts (41). To determine if Bax is recruited by vMIA to
MAM lipid rafts during infection, DRM fractions isolated from
the ER/MAM and mitochondrial fractions from HCMV wt-in-
fected HFFs at IE (12 hpi) and early (24 hpi) times of infection
previously characterized for the presence of vMIA, and control
Sigma-1 receptor (Sig-1R), erlin-2, and prohibitin (lipid raft
markers) (41) were examined for the presence of Bax (Fig. 4B).
Bax was associated with lipid rafts in the ER/MAM fractions but
not with lipid rafts in mitochondrial fractions isolated from
HCMV-infected HFFs. Thus, in a pattern similar to that of vMIA
(41), Bax associates with ER/MAM lipid rafts but not in mito-
chondrial lipid rafts from HCMV-infected HFFs.
Ubiquitinated Bax is associated with DRMs. To determine if
ubiquitinated Bax and ubiquitinated vMIA associate with DRMs,
we immunoprecipitated ubiquitinated proteins in DRM (fraction
4) and soluble (fraction 12) proteins and examined the presence of
Bax, vMIA, and total ubiquitinated proteins (Fig. 4C). Ubiquiti-
nated Bax was detected in DRMs from HCMV wt-infected HFFs
but not in those from uninfected HFFs or from STS-treated HFFs
(Fig. 4C, left). Similarly, ubiquitinated vMIA was detected in the
DRMs from HCMVwt-infected HFFs. As expected, ubiquitinated
vMIA was not found in DRMs from uninfected HFFs or STS-
treated HFFs (Fig. 4C, middle). Total ubiquitinated proteins were
readily detected in the DRM fraction of HCMV-infected cells but
not in DRMs from uninfected or STS-treated HFFs (Fig. 4C,
right). Furthermore, total ubiquitinated proteins were less abun-
dant in the soluble fractions from uninfected, STS-treated HFFs
and HCMV wt-infected HFFs. Taken together, the presence of
ubiquitinated Bax, ubiquitinated vMIA, and total ubiquitinated
proteins in DRMs suggest that their proteasome-mediated degra-
dation is associated with their MAM lipid raft localization.
Bax association with DRMs in infected cells is vMIA depen-
dent. To determine whether vMIA is responsible for Bax recruit-
ment to MAM lipid rafts during HCMV infection, we examined
the association of Bax with DRMs from HCMV UL37x1 Mut-
infected HFFs from early (24 hpi) to very late (120 hpi) times of
infection since the HCMV UL37x1 Mut is delayed in growth in
HFFs (31). In control HFFs, Bax association with DRM was de-
tected from IE through late times of HCMVwt infection (Fig. 4A).
In contrast, Bax association with lipid rafts was not detected in
HCMV UL37x1 Mut-infected HFFs at any of the times exam-
ined (Fig. 5). Cav1 served as a control for lipid raft fractions. These
results show that Bax recruitment to MAM lipid rafts during
HCMV infection is vMIA dependent.
vMIA is sufficient for Bax recruitment to lipid rafts and is
dependent on its cholesterol binding. As vMIA binds Bax and its
association with lipid rafts is dependent upon its cholesterol affin-
ity (41), we tested whether vMIA is sufficient for Bax recruitment
to lipid rafts and whether this recruitment is dependent upon
vMIA’s cholesterol binding (Fig. 6). To that end, we transfected
HFFs with expression vectors of the vMIA wt (vMIA-yellow fluo-
rescent protein [YFP]), the cholesterol binding I (CBD I-cyan
fluorescent protein [CFP]) and II (CBD II-YFP) mutants, or YFP
(vector control) (41). We then tested Bax recruitment to lipid
rafts. Bax was recruited to DRMs of HFFs transfected with expres-
sion vector of vMIA-YFP wt. However, the CBD I and CBD II
mutants, which are severely defective in MAM lipid raft associa-
tion (41), were unable to recruit Bax to DRMs. The YFP vector
control did not recruit Bax to DRMs of transfected HFFs. Caveolin
1 was used as a lipid raft fraction marker and the fluorophores
were used to detect vMIA wt-YFP, CBDI-CFP, and CBDII-YFP.
These results establish that vMIA is sufficient for Bax recruitment
to DRMs and that this recruitment is dependent upon the choles-
terol binding of vMIA.
vMIA-dependent recruitment of apoptosome components
and downstream effectors to lipid rafts. It has recently been estab-
lished that lipid rafts can serve as apoptosis-prone sites for apopto-
some assembly in cancer cells (49, 50). However, HFFs are primary,
untransformed cells. We therefore tested whether recruitment of Bax
and apoptosome components and effectors to DRMs could be de-
tected in STS-treated HFFs (Fig. 7A). Recruitment of Bax, Cyt c, Bid,
Apaf1, procaspase 9, and caspase 3 was detected in DRMs from STS-
treated HFFs. Cav1 served as a lipid raft marker. These results show
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that we could detect lipid raft association of these apoptosome com-
ponents and effectors in apoptotic HFFs.
We then examined whether vMIA is sufficient to recruit apo-
ptosome components, in addition to Bax, to DRMs and whether
its ability to bind cholesterol is required for recruitment of apop-
tosome components. DRMs were isolated from HFFs transfected
with vMIA wt or the cholesterol binding mutants, CBD I and II
(Fig. 7B). Cyt c, Bid, Apaf1, and procaspase 9 were weakly detected
in lipid rafts from transfected HFFs expressing vMIA (Fig. 7B,
upper left). Similar to Bax (Fig. 6), recruitment of Cyt c, Bid, Apaf1, or
FIG 4 (A) Bax is lipid raft associated during HCMV infection. DRMs isolated from uninfected HFFs (left) or HCMV wt-infected HFFs (right) (HCMV wt, MOI
of 3), harvested at IE (12 hpi), early (24 hpi), early/late (48 hpi), and late (72 hpi) times of infection, and characterized for the presence of vMIA and Lyn (41) were
examined for the association of Bax with DRMs. Fifteen microliters of each gradient fraction was resolved by SDS-PAGE and examined by Western analysis using
anti-Bax antibody (1:500; Millipore). (B) Bax is associated with ER/MAM lipid rafts in HCMV-infected HFFs. Flotation gradient fractions from ER/MAM and
mitochondria isolated at 12 hpi and 24 hpi from HCMV wt-infected HFFs (MOI of 3) and previously characterized for the presence of Sig-1R, erlin 2, and
prohibitin (41) were examined for the presence of Bax. Each gradient fraction (20 l) was resolved by SDS-PAGE and analyzed by Western blotting using
anti-Bax antibody. (C) Ubiquitinated Bax, ubiquitinated vMIA, and total ubiquitinated proteins were detected in the DRMs of HCMV-infected HFFs. DRMs
were isolated from uninfected, HCMV-infected (72 hpi, MOI 3), or STS-treated (50 nM, 20 h) HFFs (four roller bottles each) by cold detergent extraction and
banding on flotation gradients as previously described (41). Fractions 4 (DRM) and 12 (soluble proteins) were immunoprecipitated (IP) as described in Fig. 3.
The presence of ubiquitinated Bax (left), ubiquitinated vMIA (middle), and total ubiquitinated proteins (right) was verified by Western blot (Wb) analyses.
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procaspase 9 was not detected in HFFs expressing CBD I or CBD II
mutants or in vector-transfected HFFs. Cav1 (Fig. 6) and vMIA (Fig.
7B) served as lipid raft markers. Together, these results show that
vMIA can recruit Bax and induce the association of apoptosome
components to lipid rafts by its affinity for cholesterol.
Lipid raft association of apoptosome components is not de-
tected inHCMV-infectedHFFs.As vMIA recruited Bax to DRMs
of transfected cells and of HCMV-infected HFFs (Fig. 5 and 6) and
apoptosome components and effectors in transfected cells (Fig. 7B),
we tested whether apoptosomes were also recruited to DRMs of
HCMV-infected HFFs (Fig. 7C). Apaf1 and procaspase 9 were
weakly detected in DRMs from mock-infected HFFs. In contrast,
Cyt c, Bid, Apaf1, and procaspase 9 were not detected in the DRMs
of either HCMV wt- or HCMV UL37x1 Mut-infected HFFs at
late times of infection (72 hpi), despite the detection of Bax re-
cruitment to DRMs of HCMV wt-infected cells (Fig. 4A). Cav1
served as a lipid raft marker (Fig. 7C). Taken together, these results
suggest that HCMV infection recruits Bax to MAM DRMs using
vMIA but inhibits the recruitment of downstream apoptosome
assembly on MAM DRMs.
DISCUSSION
While the ability of vMIA to inhibit Bax proapoptotic activity is
partly responsible for its antiapoptotic activity, the mechanisms
underlying this inhibition are poorly understood and just being
deciphered (5, 7–9, 19). Herein, we demonstrate that HCMV
vMIA can inhibit apoptosis by reducing Bax levels at ER-mito-
chondrion contacts of the infected cell. We detected the expected
increased levels of Bax recruited to mitochondria during HCMV
infection, which correlate well with the previous detection of Bax
recruitment by vMIA to the OMM (5, 8, 9). In addition, we also
found an even more marked increase in Bax associated with the
MAM from IE through late times of HCMV infection.
Bax transcription does not appear to be markedly altered (2-
fold) during IE or early to early/late times of HCMV infection (72,
73). Consistently, we observe minor increases of total Bax (maxi-
mally 1.4-fold over uninfected cells) during HCMV infection,
but most of this is recruited to the MAM or mitochondria, while
free Bax decreases in the cytosol.
We show that Bax is retargeted to the MAM in a vMIA-depen-
dent manner and that vMIA is sufficient to recruit Bax to ER/
MAM lipid rafts. Significantly, Bax retargeting to the MAM re-
sulted in its increased ubiquitination and proteasome-mediated
degradation. To our knowledge, this is the first report of Bax re-
FIG 5 HCMV UL37x1 Mut does not recruit Bax to MAM lipid rafts. HFFs
were infected with the HCMV UL37x1 Mut (BADsubUL37x1) at an MOI of
1.5. DRMs were harvested from the cells at early (24 hpi), late (72 and 96 hpi),
and very late (120 hpi) times of infection and purified as in Fig. 4 and as
described previously (41). Each flotation gradient fraction (30l) was resolved
by SDS-PAGE and analyzed by Western blotting using anti-Bax (1:500; Milli-
pore) or mouse anti-Cav1 (1:500; BD Biosciences) antibodies.
FIG 6 vMIA is sufficient for Bax recruitment to MAM lipid rafts. HFFs (2 107 cells) were transfected with vectors expressing vMIA1–163-YFP, CBD I1–163-CFP,
or CBDII1–163-YFP (41). Controls were transfected with YFP vector alone. Twenty-four hours after transfection, DRMs were isolated and banded on flotation
gradients as described previously (41). Each gradient fraction (20 l) was examined by Western blotting using rabbit anti-Bax (1:500; Millipore), mouse
anti-Cav1 (1:500; BD Biosciences), and mouse anti-GFP/YFP/CFP (1:200; Santa Cruz).
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FIG 7 (A) Association of Bax and apoptosome components and effectors with DRMs following STS treatment of HFFs. HFFs were treated with STS (50 nM) for
20 h. DRMs were isolated from the STS-treated cells and banded on flotation gradients as described previously (41). Aliquots of each fraction (30 l) were
separated by SDS-PAGE and examined for the presence of Bax (1:500; Millipore), Cyt c (1:200; Abcam), Bid (1:100; Santa Cruz), Apaf1 (1:100; Santa Cruz),
procaspase 9 (1:500; GeneTex), caspase 3 (1:500; Millipore), and Cav1 (1:500; BD Biosciences) antibodies. (B) Lipid raft association of downstream apoptosome
components requires vMIA lipid raft association. HFFs (1  107 cells) were transfected with vectors expressing pUL37x11–163-YFP, CBD I1–163-CFP, or
CBDII1–163-YFP (41) and control YFP alone as in Fig. 6. Each gradient fraction (30l) was resolved by SDS-PAGE and examined using antibodies to Cyt c (1:200;
Abcam), Bid (1:100; Santa Cruz), Apaf1 (1:100; Santa Cruz), procaspase 9 (1:500; GeneTex), and vMIA (DC35, 1:2,500) or mouse anti-GFP/YFP/CFP antibodies
(1:200; Santa Cruz). Control anti-Cav1 is shown in Fig. 6. (C) HCMV infection inhibits recruitment of apoptosome components to lipid rafts. HFFs were mock
infected or infected with HCMV wt (BADwt) or the HCMV UL37x1 Mut (BADsubUL37x1) at an MOI of 1.5. Lipid rafts were isolated at 72 hpi, and gradient
fractions (30 l) were resolved by SDS-PAGE. Western blots performed using antibodies to Cyt c (1:200; Abcam), Bid (1:100; Santa Cruz), Apaf1 (1:100; Santa
Cruz), procaspase 9 (1:500; GeneTex), and Cav1 (1:500; BD Biosciences).
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cruitment to the MAM and its targeting for proteasomal degrada-
tion in association with the MAM. Our results establish MAM-
associated, ubiquitin-proteasome degradation as a mechanism for
the regulation of Bax and suggest that HCMV infection globally
increases proteasome-mediated degradation of targeted MAM
proteins, MAMAD, by late times of infection. Previously, ubiquitin-
proteasome-mediated degradation of Bax has been demonstrated to
occur by the human papillomavirus type 16 E5 protein (74). While it
is not clear if Bax degradation by HPV E5 is dependent of MAM
localization, together these studies suggest that ubiquitin-protea-
some-mediated Bax degradation may be a common mechanism em-
ployed by viruses to prevent host cell apoptosis.
HCMV infection is known to modulate the ubiquitin-protea-
some system to enhance its replication (55–58). HCMV infection
causes relocalization of some 19S proteasome subunits to the pe-
riphery of nuclear viral replication compartments (58). We de-
tected a global increase in proteasome activity in the MAM of
HCMV-infected cells at late times of infection. Consistent with
this finding, we detected using quantitative proteomics an in-
creased abundance of proteasome non-ATPase regulatory 19S
subunits (subunits 1, 2, 3, 11, and 14 with 2- to 3.5-fold increases)
in the MAM fraction of HCMV-infected HFFs at late times of
infection (37). We also found increases in ubiquitin ligase E2
UBE2N, UBE2D2, UBE2D3 (1.3- to 2.4-fold increases) but not
UBE2J1 (required for MHC class I degradation) in the MAM at
late times. Importantly, we detected an 2-fold increase in the
abundance of an E3 ubiquitin ligase (HRD1, synoviolin) required
for ERAD (75) in the MAM of HCMV-infected HFFs, but we did
not detect gp78, a known E3 ubiquitin ligase, which partially lo-
calizes to the MAM (47) and the other ortholog of yeast Hrd1p
(37). HCMV US11 targets MHC I for ERAD degradation using
derlin-1, which is in a complex with HRD1 and gp78 (75). To-
gether, our findings suggest that Bax ubiquitination is occurring
in the MAM and does not require gp78.
Some ubiquitin ligases (CHIP) link chaperones and the 26S
proteasome machinery by ubiquitinating chaperone substrates
and channeling them toward the proteasome (76–78). Chaper-
ones are among the proteins increased to the highest levels
(16.7- to 27-fold) in the MAM of HCMV-infected cells (37).
Furthermore, we detected increased levels of hsc71 (5-fold in-
crease) in the MAM of infected cells. Thus, increased MAM-asso-
ciated chaperones may play roles in the induction of proteasomal
activity of the MAM during HCMV infection.
In the MAM, Bax becomes associated with lipid rafts and depends
on the ability of vMIA to associate with cholesterol. vMIA associates
with MAM lipid rafts, as do Sig-1R and erlins (39, 41, 42). MAM lipid
raft proteins erlin-1 and -2 (SPFH1 and -2) have been found to target
IP3Rs for ubiquitination and ERAD (43), suggesting the possibility
that Bax degradation in the MAM is associated with its lipid raft lo-
cation. Our findings of increased abundance of ubiquitinated Bax,
ubiquitinated vMIA, and total ubiquitinated proteins in the MAM
but not mitochondrial fractions following MG132 treatment are con-
sistent with this possibility. Furthermore, we found that ubiquiti-
nated Bax and ubiquitinated vMIA are associated with DRMs, con-
sistent with the possibility that Bax degradation in the MAM is
associated with its lipid raft location.
Despite the finding of recruitment of Bax and of apoptosome
components to MAM lipid rafts following vMIA expression in
transfected permissive HFFs, only Bax recruitment was detected
in HCMV-infected HFFs. This finding suggests that although
vMIA is sufficient to recruit Bax and induce apoptosome associa-
tion with MAM lipid rafts, other HCMV products or HCMV-
induced cell proteins can inhibit the association of apoptosome
components with MAM lipid rafts. Reduction of apoptosome
component recruitment to DRMs will predictably reduce the pro-
pensity of these proapoptotic platforms to initiate mitochondri-
on-mediated apoptosis of HCMV-infected cells, consistent with
vMIA antiapoptotic activities in the infected cells (9, 10).
Apoptosome assembly is already known to be inhibited by a
number of proteins. For example, an alternatively spliced caspase
3 short isoform (caspase 3s) binds full-length procaspase 3 and
blocks its interaction with caspase 9 (79). Thus, caspase 3s inhibits
apoptosome assembly. Similarly, cdc6, an AAA ATPase with
multiple roles in the cell cycle, forms stable complexes with acti-
vated Apaf1 and thereby inhibits apoptosome assembly (80).
While cdc6 was not detected in our quantitative analyses of the
MAM proteome of HCMV-infected cells, we found that HCMV
infection greatly increases the abundance (12.7-fold) of two
members of the ATPase family AAA domain-containing proteins
3A and 3B in the MAM (37) and may thereby inhibit apoptosome
assembly. Alternatively, MAMAD of the apoptosome compo-
nents studied may be induced in HCMV-infected HFFs, which
would result in their reduced level in MAM DRMs, thereby pro-
tecting infected HFFs from apoptosis. Consistent with this possi-
bility is our finding that increased MAMAD in HCMV-infected
cells targets many proteins that localize to the MAM during infec-
tion. We do not yet know if the half-life of apoptosome compo-
nents is decreased during HCMV infection.
Our current model is that HCMV vMIA recruits Bax to the
MAM and then targets it for proteasome-mediated degradation.
However, steadily increasing Bax levels, which occur during infec-
tion, overwhelm the MAM system and are recruited to the OMM,
where vMIA blocks its permeabilization of the OMM. Even
though Bax is increasingly associated with the MAM of HCMV-
infected cells and degraded, as infection progresses, Bax is also
detected in increasing levels in mitochondria. It appears that the
increasing levels of activated Bax cannot be neutralized solely by
recruitment to the MAM and MAMAD. Thus, HCMV has evolved
complementary yet redundant mechanisms to block Bax proapo-
ptotic activity in the infected cell.
Although Bax is increasingly recruited to the OMM during
infection, we did not detect HCMV induction of OMMAD deg-
radation of Bax, which is known to regulate activated Bax activity
in uninfected cells (51–54). In the absence of HCMV infection,
ubiquitin proteasome degradation of Bax is known to be induced
by mitochondrial ubiquitin E3 ligase parkin (52). This mechanism
is known to regulate Bax proapoptotic function and to underlie the
antiapoptotic function of parkin. In mitochondria, the activated
form of Bax is selectively targeted for degradation (54). Thus, HCMV
infection seems to selectively increase the ER/MAM-associated ubiq-
uitin-proteasome machinery but not OMMAD.
Together, our results show that HCMV utilizes vMIA to block
Bax proapoptotic activities in the infected cell by two distinct
mechanisms, the first being its previously recognized inhibition of
Bax-mediated permeabilization of the OMM (5, 7–9, 19) and the
second, as demonstrated herein, the recruitment and increased
degradation of Bax in the MAM subcompartment of the ER. Fur-
thermore, the HCMV antiapoptotic program also involves the
reduction of apoptosis-prone platforms in the MAM DRMs by a
mechanism reducing the association of apoptosome components.
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Thus, HCMV infection independently blocks mitochondrion-
mediated apoptosis by a previously unrecognized mechanism us-
ing MAM-associated proteasome-mediated degradation.
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